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Pharmacological stimulation of fetal hemoglobin (HbF) expression may be a promising approach for the treatment of beta-
thalassemia. In this study, the eﬀects of Fructus trichosanthis (FT) were investigated in human erythroleukemic K562 cells for
theirgamma-globinmRNAandHbF-induction activities. The roleofsignalingpathways,includingextracellular regulated protein
kinase (ERK) and p38 mitogen-activated protein kinase (MAPK), was also investigated. It was found that the ethanol extract of
FT signiﬁcantly increased gamma-globin mRNA and HbF levels, determined by real-time reverse transcription polymerase chain
reaction and enzyme linked immunosorbent assay, respectively, in dose- and time-dependent manner. Total Hb (THb) levels were
alsoelevatedintheconcentrationswithoutcytotoxicity (<80μgmL −1).Pre-treatment withp38MAPKinhibitorSB203580blocked
the stimulatory eﬀects of FT extract in total and HbF induction. In contrast, no change in HbF was observed when treated with
ERK inhibitor PD98059. Furthermore, FT ethanol extract activated p38 MAPK and inhibited ERK signaling pathways in K562
cells, as revealed in western blotting analysis. In addition, SB203580 signiﬁcantly abolished p38 MAPK activation when the cells
were treated with FT. In summary, the ethanol extract of FT was found to be a potent inducer of HbF synthesis in K562 cells.
The present data delineated the role of ERK and p38 MAPK signaling as molecular targets for pharmacologic stimulation of HbF
production upon FT treatment.
1.Introduction
β-Thalassemia is an inherited autosomal recessive disease
commonly found in the Mediterranean, southeast Asia and
southern China [1, 2]. It is caused by mutations in the beta-
globin gene on chromosome 11p15.5. Patients suﬀer great
morbidity and mortality, including transfusion-dependent
anemia with concomitant iron overload, hepatosplenomega-
ly and ineﬀective erythropoiesis [3]. Increased fetal hemo-
globin (HbF) production can compensate for the shortfall
of adult Hb (HbA) synthesis in β-thalassemia patients [4].
Some chemotherapeutic agents, such as hydroxyurea (HU)
and 5-azacytidine have been used to enhance HbF produc-
tion [5, 6], but myelotoxicity, fear of long-term carcinogene-
sis and only modest responses to treatment have limited the
clinical usefulness of these agents [7, 8]. In view of the lack
of good therapeutic agents for this disease, we established a
rational strategy on discovering new interventions to reac-
tivate HbF production in Chinese herbal medicines by using
human erythroleukemiacellline K562asscreening platform.
Our pilot studies showed that the ethanol extract of Fructus
trichosanthis (FT) could induce HbF production in vitro.
FT, the fruit of Trichosanthes kirilowii MAXIM, is one of
the most frequently used Chinese herbs. According to the
theory of Chinese medicine, FT is useful in treating cough
due to phlegm-heat and treating the accumulation of cold-
phlegm [9]. In addition, FT has been used in the treatment
of diabetes, bronchial diseases, breast cancer, leukemia and
Ehrlich’s ascitic carcinoma in various folk remedies. How-
ever, scientiﬁc evidence on its biological activities is very2 Evidence-Based Complementary and Alternative Medicine
limited. Only one well-documented study demonstrated that
themethylene chloride fraction ofFT inhibited theprolifera-
tion and induced apoptosis in human leukemicU937 cells in
vitro [10]. Human erythroleukemia cell line K562 has been
previously shown to be Philadelphia-chromosome positive.
The expression levels of both embryonic Hb (Hb Gower and
Hb Portland) and HbF is markedly increased after exposure
to hemin [11]. This cell line appears to be committed
alongtheembryo-fetalerythroiddiﬀerentiationpathwayand
produces Hb independently of terminal diﬀerentiation [12].
Thus, it has been used extensively as a model system for
the investigation of human globin gene regulation and HbF-
inducer screening [13].
In order to determine the HbF-inducing eﬀect of FT, the
present study was designed to investigate the eﬀect of FT on
K562 erythroid diﬀerentiation. We found that the ethanol
extract of FT promoted gamma-globin (γ-globin) mRNA
expression and HbF production in K562 cell cultures. The
inducing eﬀect appeared to be due to the activation of p38
mitogen-activated protein kinase (MAPK) signaling pathway
and the inactivation of extracellular regulated protein kinase
(ERK) signaling pathway.
2.Methods
2.1. Plant Extraction. T h er a wm a t e r i a l so fF Tw e r ep u r -
chased from herbal pharmaceutical company in Hong Kong
and authenticated in accordance to Chinese Pharmacopeia
[14]. The reference herbs were purchased from the National
Institute for the Control of Pharmaceutical and Biological
Products in China. The authenticated voucher specimens
were deposited in the Institute of Chinese Medicine, The
Chinese Universityof HongKong.Forethanol extract prepa-
ration, 500g of dried FT was extracted by 2 l of 95% ethanol
at 60◦C for 24h. This extraction step was repeated twice.
After simple percolation, the collected ethanol solution was
rotary evaporated at 65◦C until the inner matters become
viscous semi-solid. The viscous content of the extract was
precipitated out by adding 2.5 volume of 40% ethanol and
discarded. The ethanol content of the solution was then
removed by rotary evaporation and lyophilized by freeze
dryer. The powdered form of the extract was stored in a
desiccator at room temperature until use.
2.2. K562 Cell Culture and Treatment Protocol. Human ery-
throleukemic K562 cells were obtained from the American
Type Culture Collection. K562 cells were cultured in RPMI-
1640 medium (supplemented with 10% fetal bovine serum
and 1% penicillin-streptomycin) under a humidiﬁed atmo-
spherewith5%CO2 at37◦C.Thecellswere thensubcultured
at 1 × 104 cellsmL−1 when they reached semi-conﬂuence.
FT ethanol (FT-EtOH) extract was reconstituted in
dimethyl sulfoxide (DMSO) for the cell culture. The concen-
tration of DMSO was adjusted <0.1% of ﬁnal concentration
of culture medium which causes no cytotoxic eﬀect to the
cells. Cells were treated with FT-EtOH extract and a known
positive control HU at various concentrations. In the study
of cytotoxicity, K562 cells were seeded in 96-well plates at
4 × 103 cells/well in RPMI and treated with drugs for 48h
at 37◦C. For total Hb (THb) and HbF assays, the cells were
seeded in 96-well plates at 4 × 103 cells/well and the mea-
surements were taken daily throughout 6 days of treatment.
In order to elucidate the underlying signaling pathways,
inhibitors of ERK—PD98059 (25μM)—and p38 MAPK—
SB203580 (10μM)—were added on K562 cultures prior to
FT treatment, followed by the THb and HbF quantiﬁcations,
as well as western blotting analysis. The concentration of FT-
EtOH extract was optimized at 20μgmL −1 for mechanistic
studies in our pilot experiments.
2.3. Cytotoxicity Assay. The cytotoxic eﬀect of FT extract
was determined using 1-(4,5-dimethylthiazol-2-yl)-(3,5)-di-
phenyl-formazan (MTT) colorimetric assay. In brief, after
48h of drug treatment, MTT solution (5mgmL−1 in phos-
phate buﬀered saline) was added to each well and incubated
at37◦Cfor3h.The blueformazan crystalsthatresultedfrom
thereductionofMTTbyliving cellswere dissolvedinDMSO
and the absorbance was measured at 540nm. Cell survival
was determined as a percentage of viable cells in treated cells
versus no drug-treated control group.
2.4. THb Assay. The relative THb production of K562 cells
was determined by 3,3,5,5-tetramethylbenzidine (TMB) as-
say, which is based on the peroxidase-like activity of heme
portion of Hb. At each timed interval, the cells of each
treatment group were reacted with 5% TMB (w/v) solution
at37◦Cfor10minindarkness, followedbyreactiontermina-
tionbyadding2MH2SO4.Thenumberofstained(blue)and
unstained (pale yellow) cells were counted under inverted
microscope. The relative THb production was expressed as
(number of stained cells/total number of cells) × 100%.
The quantitative amount of Hb was determined by using
the plasma Hb kit (Sigma) according to the manufacturer’s
instruction.
2.5. HbF Assay. HbF levels of K562 cells were determined
quantitatively by commercially available enzyme linked im-
munosorbent assay (ELISA) kit (Bethyl). At each time
interval, diluted cell lysate (in 50mM Tris-Cl/1% BSA) was
transferred to 96-well plate, which was pre-coated with
anti-HbF, and incubated at room temperature for 1h. The
secondary antibody, horse radish peroxidase, was conjugated
to primary antibody for 1h followed by the addition of 10%
TMB solution. The reaction was terminated by adding 2M
H2SO4 and the absorbance was determined at 450nm. The
concentration of HbF was determined in reference to the
standard curve and expressed as HbF per total proteins.
2.6. Quantitative Real-Time Polymerase Chain Reaction on α-
and γ-Globin mRNA. The cells were seeded onto six-well
plate at a density of 1 × 104 cellsmL−1 and incubated with
corresponding FT-EtOH extract at various concentrations
and HUfor 6 days at 37◦C. After 6 daystreatment, totalRNA
was isolated from cultures of each experimental group using
RNeasy mini kit according to manufacturer’s instruction
(Qiagen). Eighty nanograms of total RNA extracted fromEvidence-Based Complementary and Alternative Medicine 3
each treatment group were subjected to one-step real-time
reverse transcription polymerase chain reaction (RT-PCR)
using the QuantiFast SYBR Green RT-PCR kit (Qiagen)
with ABI 7500 Fast Real-Time PCR System. α-a n dγ-
globin gene-speciﬁc primers were design customized and
validated by manufacturer (Hs HBA1 2 SG, QT01671215;
Hs HBG2 1 SG, QT00040068; QuantiTect Primer Assays;
QIAGEN). Each reaction mix contained the following: 80ng
RNA, IμM of each primer, 12.5μL2× QuantiTect SYBR
green RT-PCR master mix, 0.25μL QuantiTect reverse tran-
scriptase mix and nuclease-free H2Ot o2 5μL. The following
thermal cycling conditions were used: for reverse transcrip-
tion,10minat50◦C;forthePCRinitialactivationstep,5min
at 95◦C; for ampliﬁcation, 15s at 95◦C, 30s at 55◦Cf o r4 5
cycles. Melting curve analysis of the RT-PCR products was
done in order to verify the speciﬁcity and identity of the
PCR products. For each sample, real-time RT-PCR analysis
was done with a reference gene (glyceraldehyde-3-phosphate
dehydrogenase gene, GAPDH) as an internal control.
Relative gene expression levels are presented as 2(−ΔCt),
where ΔCt = Cttarget − CtGAPDH and the Ct value is the cycle
threshold. The SD was determined from three independent
experiments of the ΔCt values. The upper and lower errors
were deﬁned as 2−(ΔCt−SD) and 2−(ΔCt+D), respectively. Fold
change for the treatment group was deﬁned as the relative
expression, compared with the control group without treat-
ment and was calculated as 2(−ΔΔCt),w h e r eΔΔCttreatment =
ΔCttreatment – ΔCtcontrol.
2.7. Western Blotting Analysis. Treated K562 cells were lysed
in 200μL of ice-cold lysis buﬀer (50mM Tris, 150mM
N a C l ,2m ME D T A ,5 0m MN a F ,0 . 2m Ms o d i u mv a n a d a t e ,
1% SDS, 1mM phenylmethylsulphonyl ﬂuoride, 1μgmL −1
aprotinin and 1μgmL −1 leupeptin), and protein concen-
trations were determined using bicinchoninic acid assay.
Cytosolic extracts (20μg) were subjected to SDS-poly-
acrylamide gel electrophoresis using 10% polyacrylamide
gels and transferred to polyvinylidene uoride membranes
(Biorad). Membranes were blocked with Tris-buﬀered saline
containing 0.1% Tween-20 and 10% dry milk for 1h and
then incubated overnight at room temperature with diluted
primary antibodies (anti-ERK1/2 phosphorylated, anti-
ERK1/2 total, anti-stress-activated protein kinase/c-Jun
NH2-terminal kinase (SAPK) phosphorylated, anti-SAPK
total, anti-p38 phosphorylated and anti-p38 total antibod-
ies; Calbiochem). After incubation, the membranes were
washed with TBS-T followed by incubation for 1h with sec-
ondary antibodies conjugated horseradish peroxide diluted
at 1:3000. The proteins of interest were visualized by the
chemiluminent protein detection system according to the
manufacturer’s instructions (Biorad).
2.8. Statistical Analysis. All data are expressed as mean ±
standard deviation (SD). All the statistical analysis were
performed by software SigmaStat version 3.5 (SPSS Science
Software GmbH, Erkrath, Germany). Statistical signiﬁcance
was compared between each treatment groups and control
group by one-way ANOVA followed by post-hoc Dunnett
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Figure 1: The eﬀect of FT-EtOH extract on the cell viability and
THb induction in K562 cells. (i) K562 cells were treated with
indicated concentrations of FT-EtOH extract for 2 days. The cell
viability (ﬁlled square) was then estimated by MTT assay. (ii) K562
cells were treated with indicated concentrations of FT extract for
6 days. The Hb-positive cells were stained by TMB assay and the
percentage of stained cells (ﬁlled triangle) was calculated. The
results are expressed as mean ± SD of three cultures. The data are
representative of three separate experiments. #P<. 05, signiﬁcant
diﬀerence in cell viability when compared with non-treated group.
∗P<. 05, signiﬁcant diﬀerence in the number of TMB-stained cells
when compared with non-treated group.
test. Values with P<. 05 were considered as statistically
signiﬁcant. Values of IC50 and EC50 were determined by
non-linear regression dose-response curve.
3.Results
3.1. Cytotoxicity Assay. The cytotoxic eﬀect of FT-EtOH
extract on K562 cells is shown in Figure 1.T h e r ew a sad o s e -
dependent inhibitory eﬀect of FT-EtOH extract. Signiﬁcant
cytotoxic eﬀect was found when the cells were treated with
≥80μgmL −1 extract. The IC50 of the FT-EtOH extract was
108.6μgmL −1.
3.2. THb Assay. Our results demonstrated that the FT-
EtOH extract induced THb formation in the range without
cytotoxic eﬀects. At 40μgmL −1, the extract exerted its max-
imal eﬀect on THb production by 78.0 ± 4.2% (Figure 1).
Beyond this concentration, the degree of Hb induction was
decreased, possibly due to increasing cytotoxic eﬀect as
found in MTT assay.
Time-dependent response of THb-induction eﬀect of
FT-EtOH extract is shown in Figure 2. From day 3 to day 6,
there was a signiﬁcant increase of TMB-positive cell percent-
age at all test concentrations of FT extract when compared
with their respective basal values on day 1. Our data showed
that the optimal dosage of this extract was 40μgmL −1,
which gave similar time-dependent Hb-inducing eﬀect as
positive control HU at 25μgmL −1. In the control group,
the percentage of TMB-positive cells was slightly increased
(<15%). It indicated that auto-diﬀerentiation of K562 cells
was found in prolong culture.4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: The eﬀect of FT-EtOH extract and HU (25μgmL −1)o n
inductionofTHb ofK562cells atdiﬀerent timeintervals.K562cells
were treated with indicated concentrations of FT extract and HU
for 6 days. The Hb-positive cells were stained by TMB assay. The
results are expressed as mean ± SD of three cultures. The data are
representative of three separate experiments.
3.3. HbF Assay. There was a signiﬁcant increase of HbF at all
tested concentrations (20–80μgmL −1)o fF T - E t O He x t r a c t
when compared with untreated cell control [Figure 3(a)).
Dose-dependent response of FT-EtOH extract was observed
in the range of 20–40μgmL −1. The maximal response
was observed at 40μgmL −1. Beyond this dose, the HbF-
inducing eﬀect of FT was diminished, possibly due to its
cytotoxic eﬀects at higher dose. Time-dependent eﬀect of
FT-EtOH extract was also demonstrated during 6 days of
incubation (data not shown). Similar HbF-inducing eﬀect
was demonstrated in HU (25μgmL −1) group, it increased
the HbF concentration signiﬁcantly over 6 days of culture
period. During the experiment, auto-diﬀerentiation of K562
cells was found in the untreated control cells starting from
day 4 to day 6 (data not shown). However, the degree
of increase was smaller than both treatment and positive
control groups.
To investigate the speciﬁcity of FT-EtOH extract on HbF
stimulation, we determined the HbF to THb ratio. FT-EtOH
extract increased the proportion of HbF relative to total
K562cells. At40μgmL −1,FT-EtOH extract causeda 2.6-fold
increase of the HbF ratio compared with untreated control
cells, its HbF-inducing eﬀects were similar to the positive
control HU.
3.4. Quantitative Real-Time PCR on α-a n dγ-Globin mRNA.
Following 6 days of treatment, γ-globin mRNA level was
increased signiﬁcantly at all investigated concentrations
(20–80μgmL −1)o fF T - E t O He x t r a c tw h e nc o m p a r e dw i t h
untreated cell control (Figure 4).This extract showed a dose-
dependent eﬀect on γ-globin mRNA induction in the range
of 20–40μgmL −1.A t4 0 μgmL −1,t h em R N Al e v e lo fγ-
globinwasincreased4.8 ± 0.5foldcomparedwithuntreated
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Figure 3: The eﬀe c to fF T - E t O He x t r a c ta n dH U( 2 5 μgmL −1)
on HbF production of K562 cells. Dose-dependent HbF-inducing
eﬀects of FT-EtOH extract on K562 cells after 6 days of treatment,
expressed in (a) percentage of HbF per total proteins and (b)
percentage of HbF per THb. The HbF concentration of each group
was quantiﬁed by commercial ELISA kit. The results are expressed
asmean ± SDofthree cultures. The dataare representative ofthree
separate experiments. ∗P<. 05, signiﬁcantly diﬀerent from non-
treated control group.
control cells. The induction eﬀect of FT-EtOH extract on γ-
globin mRNA expression was diminished at higher concen-
trations. Similar response was observed in HU (25μgmL −1)
group that showed 5.2 ± 0.6 fold increase. The mRNA
expression of α-globin was also increased, but to a lesser
extent. At 40μgmL −1,t h em R N Al e v e lo fα-globin was
increased by 3-fold. Our data implied that FT-EtOH extract
exhibits relative speciﬁcity forγ-globin mRNA expression, as
suggested by the protein data.
3.5. Inhibitory Eﬀects of Speciﬁc MAPK Inhibitors on FT-
Treated Cultures. To determine whether MAPK-mediated
signaling pathways are involved in the FT-driven HbF induc-
tion,theactionsofERKinhibitorPD98059andp38inhibitor
SB203580 in FT-treated K562 cultures were examined.
As shown in Figure 5(a), SB203580 signiﬁcantly inhibitedEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: The eﬀe c to fF T - E t O He x t r a c ta n dH U( 2 5 μgmL −1)
on α- (ﬁlled square) and γ-globin (open square) expressions of
K562 cells. K562 cells were treated with indicated concentrations
of FT-EtOH extract and HU for 6 days. The mRNA expression of
α-a n dγ-globin gene of each group was quantiﬁed by real-time
P C R .T h er e s u l t sa r ee x p r e s s e da sm e a n± SD of three cultures.
The data are representative of three separate experiments. ∗,#P<
.05, signiﬁcantly diﬀerent from corresponding non-treated control
group.
the FT-induced Hb production completely by 48%, whereas
PD98059 did not pose any signiﬁcant eﬀects on FT-treated
culture. Similarly, p38 inhibitor SB203580 also signiﬁcantly
decreased FT-induced HbF synthesis (Figure 5(b)). On day
6, the percentage of HbF/total proteins of FT plus SB group
was 17.2 ± 0.7, which was signiﬁcantly lower than FT group
by 50%. On the other hand, the ERK inhibitor PD98059 did
not alter the production of HbF signiﬁcantly (P>. 05) when
compared with FT group.
3.6. Western Blotting Analysis on Signaling Pathways. The
p38, ERK and SAPK pathways are thought to be involved
in HbF activation. We tested whether FT aﬀected these
pathways on K562 cells. As shown in Figure 6(a),n o t i c e a b l e
basal levels of p-ERK and p-SAPK were found, since both
the proteins were actively involved in cell proliferation
and survival at undiﬀerentiated state [15, 16]. For p38, it
was substantially phosphorylated after 10min of FT-EtOH
extract addition and this phosphorylation was sustained
for the entire observation period. In contrast, ERK was
de-phosphorylated upon FT treatment in time-dependent
manner. However, no signiﬁcant change was found in the
phosphorylation ofSAPKprotein. Inaddition, the treatment
of p38 inhibitor SB203580 down-regulated the FT-induced
phosphorylation of p38 (Figure 6(b)). These results indicate
that activation of p38 is essential for FTinduced HbF
production.
4.Discussion
To date, the use of extracts from medicinal plants for bi-
omedical purposes is increasing for the treatment of vari-
o u sd i s e a s e ss u c ha sd i a b e t e sm e l l i t u s[ 17], cardiovascular
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Figure 5: The eﬀect of MAPK inhibitors on FT-induced total
HbF expression in K562 cells. Cells were cultured in the presence
of 20μgmL −1 FT-EtOH extract with addition of ERK-inhibitor
PD98059 (PD) and p38-inhibitor SB203580 (SB), respectively. (a)
The number of TMB-stained cells and unstained cells was scored
under inverted microscope at200x magniﬁcation.The relative THb
production of K562 cells was expressed as a percentage of number
of stained cells in reference to total number of cells. (b) The
concentration of HbF was determined in reference to the standard
curve ofHbF andexpressed in percentage ofHbF per totalproteins.
T h er e s u l t sa r ee x p r e s s e da sm e a n± SD of three cultures. The data
are representative of three separate experiments.
diseases [18] and bone disorders [19]. However, for the case
of β-hemoglobinpathies, only fewe x a m p l e sa r ea v a i l a b l e .
For instance, Niprisan (Nix-0699), a ethanol/water extract
from Nigeria indigenous plants, demonstrated a signiﬁcant
anti-sickling eﬀects in vitro and in vivo [20, 21]. Recently,
bergamot fruit extracts was recently reported as a good γ-
globin gene expression inducer in both K562 and human
progenitor cells [22]. The extract of Ayurvedic herb, Aegle
Marmelos was also found to be associated with the activation
of erythroid diﬀerentiation and HbF induction in K562
humanerythroleukemiacells[23].Inaddition,phyotochem-
icals (i.e., angelicin and resveratrol) were shown to be potent
inducersoferythroiddiﬀerentiationandgamma-globingene
expression in either K562 or human erythroid progenitor
cells [24, 25].6 Evidence-Based Complementary and Alternative Medicine
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Figure 6: The eﬀect of FT-EtOH extract on MAPK-mediated
signaling pathways. (a) K562 cells were treated with FT extract
for 10min. Cells were lysed and analyzed by western blotting with
antibodies probing the phosphor- and total forms of p38, ERK and
SAPK. (b) K562 cells pre-treated with p38-inhibitor SB203580 (SB)
for 10min in the presence of FT-EtOH extract for 10min. Cells
were lysed and analyzed by western blotting. Similar results were
obtained in three separate experiments.
In the present study, we found that the ethanol extract of
FT, like HU, signiﬁcantly increased the production of HbF in
K562 cells. This was indicated by the increase of HbF protein
levelsand γ-globin mRNAsynthesis, following the treatment
with FT extract. THb levels were also elevated. We found
that the activation of HbF synthesis involved the inhibition
of ERK and activation of p38 MAPK signaling pathways
as shown in western-blotting analysis. Speciﬁc inhibition
of p38 signaling by SB203580 inhibited FT-EtOH-mediated
induction of Hb production. Figure 7 shows a schematic
drawing summarizing the experimental results.
Our results demonstrated that FT-EtOH extract is eﬀec-
tive in increasing γ-globin mRNA synthesis and HbF pro-
duction in the concentrations without killing the cells. FT is
long regarded as non-toxic because it has been used in China
FT ethanol extract
p38 MAPK
γ-globin expression
Fetal haemoglobin
Total haemoglobin
K562 cell
SAPK
(no eﬀect)
ERK
Figure 7: Hypothetical diagram to illustrate the actions of FT-
EtOH on MAPK family in HbF induction. After FT-EtOH treat-
ment, activation of p38 and inhibition of ERK lead to HbF pro-
duction and subsequently increase total hb level in K562 cell.
However, SAPK does not involve in FT-EtOH-induced erythroid
diﬀerentiation process.
over thousands of years with no severe adverse side-eﬀects.
This extract is relatively safe for long-term treatment, when
compared with HbF-inducing chemotherapeutic agents. In
addition, it was recently reported that accelerated apoptosis
of erythroid progenitors in β-thalassemia is a major obstacle
of deﬁnitive therapy, since most of the HbF-inducing agents
are cytotoxic that inhibits the cell proliferation and cause
cell growth arrest [26]. As a result, the beneﬁcial eﬀects of
these agents on globin chain balance may not be inducible in
apoptotic cells. Because of this, agents with low cytotoxicity,
such as FT-EtOH extract, may decrease the cellularapoptosis
of β-thalassaemic erythroid cells and provide more favorable
conditions for eﬀective erythropoiesis.
We studied three signaling cascades related to erythroid
diﬀerentiation, including p38 MAPK, ERK and SAPK. It has
been reported that HU mediates erythroid diﬀerentiation
and HbF production by inhibition of ERK and activation
of p38 MAPK signal transduction pathways [27]. Our
results were in line with those reports, suggesting that the
eﬀects of FT-EtOH extract on erythroid diﬀerentiation in
K562 cells share some similarities. In K562 cells, activation
of ERK signaling leads to megakaryocytic diﬀerentiation,
while inhibition of ERK pathway enhances the erythroid
phenotype and also the γ-globin mRNA expression [28].
In addition, ERK pathway inhibitor U0126 was reported to
induce γ-globin expression and HbF formation in human
erythroid progenitor cells [29]. Recently, Mabaera et al.
suggested that p38 MAPK plays a central role in HbF re-
activation [30]. p38 MAPK signal pathway is activated by
various environmental stresses and has been suggested to
play a critical role in apoptosis, cell growth and erythroid
diﬀerentiation. There has been accumulating evidence from
K562 cells and human progenitor erythroid cells on the
involvement of p38 MAPK up-regulation in HbF-induction
process [31, 32]. Furthermore, p38 MAPK signaling path-
way has been implicated in the actions of several HbF-
inducing agents, including butyrate [33], apicidin [34]a n d
trichostatin A [35]. Our present study suggests that FT-
EtOH extract induced erythroid diﬀerentiation and HbFEvidence-Based Complementary and Alternative Medicine 7
production by inhibiting ERK and activating p38 MAPK
signaling transduction. However, the action mechanism for
the activation or inactivation of MAPKs is still not clear. It
wasproposedthatmultipleupstreamsignals, includingDNA
damage, oxidative stress, heat shock, osmotic shock, nitric
oxide and inhibition of protein synthesis would activate
the downstream kinases and transcription factors for HbF
production [30].
Recently, there were conﬂicting reports concerning the
involvement of SAPK in erythroid diﬀerentiation [27, 32,
33, 36]. Activation of SAPK was shown to be essential for
erythropoietin-induced erythroid diﬀerentiation of mouse
erythroleukemia cells [32]. However, a signiﬁcant inhibition
of SAPK was found when the K562 cells were treated with
HU [27]. Apart from these ﬁndings, short chain fatty acid
derivatives (SCFAD),such as butyrate and valproate, did not
cause any eﬀect on SAPK pathway in K562 cells [33, 36].
Therefore, the role of SAPK in HbF induction still remains
to be elucidated. In our present study, FT-EtOH extract did
not cause SAPK phosphorylation and it was found to induce
asimilar patternofMAPKmodulation asSCFAD,suggesting
that both of them have intracellular signaling pathways in
common.
The major limitation of our study is that FT-EtOH ex-
tract contains numerous compounds. Their respective phar-
macokinetics and biotransformation properties in vivo are
notwell-deﬁned. The activecompoundsmay be metabolized
before they exert direct eﬀects on erythroid progenitor cells,
especially for those orally administrated therapeutics. In
addition,FT-EtOHextractmaycontainothersubstancesthat
interfere with the biological actions of the active ingredients
in vivo. Therefore, development of β-thalassemia animal
model is important for accurately predicting the therapeutic
eﬀects in vivo.
In summary, our results present the ﬁrst evidence on the
HbF-inducing actions of ethanol extract of FT on K562
cells as demonstrated by the elevation of γ-globin mRNA
expression and HbFlevels.The inductioneﬀectsofFT-EtOH
extract might be mediated by its direct action of stimulating
p38 MAPK and inhibiting ERK signaling pathways. Our
observations would serve as groundwork for further studies.
In order to develop FT-EtOH extract in the international
scientiﬁc community as an alternative regime for the
treatment of β-thalassemia by HbF stimulation, additional
speculation awaits the illustration of the eﬀect of FT-EtOH
extract on primary precursor cells from normal donors or β-
thalassaemic patients. And also additional experiments will
be required to perform acute and chronic toxicity test in
vivo to ensure the extract is safe for clinical use on human
subject. Finally, the eﬃcacy of the extract will be examined
in clinical evaluation. It is anticipated that FT-EtOH extract
is a promising alternative and complementary agent for the
management of β-thalassemia.
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